Cancers Supplementary tables and figures

List of Supporting Information:

Fig. S1. Kaplan–Meier analysis of progression-free survival among patients with unresectable advanced hepatocellular carcinoma treated with lenvatinib (Figure S1a) and atezolizumab+bevacizumab (Figure S1b).

Fig. S2. Kaplan–Meier analysis of overall survival among patients with unresectable advanced hepatocellular carcinoma treated with lenvatinib (Figure S2a) and atezolizumab+bevacizumab (Figure S2b).

Fig. S3. Recurrence-free survival with Kaplan–Meier curve in patients with and without drug therapy after conversion therapy (Figure S3a). Kaplan–Meier analysis of recurrence-free survival among patients by conversion treatment (Ablation vs. Hepatectomy) (Figure S3b).

Fig. S4.  Flowchart of the propensity score matching. Age, sex, Child-Pugh score, ECOG-PS, Eastern Cooperative Oncology Group performance status and Vp were included as propensity score marching factors.

Table. S1. Response to treatment with lenvatinib and atezolizumab plus bevacizumab for hepatocellular carcinoma

Table. S2. Baseline patient characteristics of conversion cases

Table. S3. Characteristics of patients with unresectable hepatocellular carcinoma treated with and without conversion therapy in propensity score matching cohort.